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Summary 
 
 
1. Summary 
The current thesis briefly introduces the dopamine system and specifically elucidates the 
role of the dopamine transporter within synaptic transmission. Knowledge from genetic, 
molecular, pharmacological and animal literature is summarized, in order to gain an 
understanding of the functional role of the dopamine transporter within cognitive and 
behavioural concepts. Converging literature emphasize the transporters crucial role on 
dopaminergic tone which is due to the impact on the allocation of extra- and intracellular 
dopamine.  
The methodological part describes invasive and non-invasive neuroimaging modalities 
for the measurement of genetic and molecular influence of the human dopamine 
transporter. Additionally, analysis processes and gene expression that are applied in the 
experimental part are described in this section.  
The experimental part presents theoretical background and outcome of three independent 
original studies that broadened knowledge of the influence of dopamine transporter on 
human cognition. The first study reveals a modulation of brain activation during 
inhibitory motor control as function of a genetic variant that potentially predicts striatal 
dopamine transporter density. In the absence of performance effects the dopamine 
transporter genotype shows a consistent effect on brain activation in contrast to another 
dopaminergic genotype of prefrontal function. The second study, investigated genetic and 
molecular predictors of a single dose of a dopamine transporter inhibitor, namely 
methylphenidate. The findings revealed an interaction between genotype and 
pharmacological intervention and implies genetic variability in the treatment outcome of 
catecholamine transporter inhibitors. The third study used the same compound in order 
to dissociate specific effects of striatal dopamine modulation from secondary dopamine 
stimulation with a cholinergic agent (nicotine) during an oculomotor task. In the absence 
of performance differences, an increase in the left frontal eye field was observed with a 
single dose methylphenidate. In contrast, nicotinic stimulation showed a reduction of 
brain activation.  
The general discussion embeds the findings within the context of cognition and behaviour 
and suggests an explanation for the observed genetic and interaction effects in the context 
of synaptic dopamine transmission. Finally, overall limitations of the presented data is 
discussed.   
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"...what draws us into a story and keeps us there is the firing 
of our dopamine neurons, signaling that intriguing 
information is on the way." 
 
Author: Lisa Cron,  
Wired for Story: The Writer’s Guide to Using Brain Science to Hook Readers from the Very First Sentence 
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4. Theoretical Framework 
The theoretical background of this thesis introduces the neurotransmitter dopamine and 
specifically focus on the role of the dopamine transporter within dopaminergic 
functioning and its modulatory role in cognition. Successively, the theoretical framework 
is complemented by three empirical studies investigating dopaminergic transmission in 
human cognition.  
4.1 Dopamine 
Dopamine belongs to the small-molecule neurotransmitter category. Since its first 
detection (Dahlström and Fuxe, 1964) there has been a fast growing interest in its 
functional role. Although not immediately accepted by neuroanatomists, the initial major 
locations of dopaminergic neurons were attributed to the mesencephalon and the 
diencephalon. Early focus remained on the projection from the substantia nigra, pars 
compacta to the neostriatum and later to the projection between the ventral tegmental area 
and the olfactory tubercle and the ventral striatum (Moore and Bloom, 1978).  
With the development of optical and ultrastructural immunocytochemistry an increasing 
understanding of the extent and organization of the dopamine neurons established in the 
late 1970s (Iversen et al., 2010). Although, early work had identified a small, but 
concentrated projection of dopamine fibres in rodent prefrontal cortex, the discovery of 
dopamine fibres in the primate medial prefrontal cortex twenty years later (Lewis, 1992) 
formed the groundwork for the investigation of dopamine effects within cortical circuitry 
and its role in cognition. The rising interest in dopamine has been accelerated by its 
association with psychiatric disorders, such as schizophrenia (Howes and Kapur, 2009), 
addiction (Volkow, Wang, Telang, et al., 2007), attention deficit hyperactivity disorder 
(ADHD) (Sikström and Söderlund, 2007), personality disorders (Mohr and Ettinger, 
2014) and neurodegenerative disorders (Hirano, Shinotoh and Eidelberg, 2012). 
Early interpretations named dopamine an ‘inhibitory’ transmitter (Connor, 1970; Mantz 
et al., 1992; Thierry et al., 1998), yet this description does not come close to the 
complexity of action triggered by dopamine. Neuromodulator is a far more appropriate 
portrayal of dopamine and gives justice to its highly complex pattern of action. A 
neuromodulatory role is assigned to transmitters that do not alter basal neuronal activity, 
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but promote or weaken evoked responses to other transmitters (Barchas et al., 1978). 
To fulfil this role, dopamine neurons possess distinct presynaptic mechanisms that allow 
‘tonic’ and ‘phasic’ modes of firing and postsynaptic mechanisms regulating duration of 
receptor stimulation and direction of effect following D1 or D2 receptor activity (Grace 
and Bunney, 1984a, 1984b; Pucak and Grace, 1994). Tonic firing describes spontaneous 
single spike activity which has been associated with behavioural flexibility (Goto, Otani 
and Grace, 2007). Thus, the number of dopamine neurons influences the baseline tonic 
level (Grace, 1991; Floresco et al., 2003). Burst firing or phasic activity triggers high 
amplitude intrasynaptic dopamine release and is subject to rapid dopamine transporter 
reuptake (Grace, 1991; Floresco et al., 2003; Floresco, 2013; Gowrishankar, Hahn and 
Blakely, 2014). 
Decline in motor function, cognitive flexibility, inhibition and working memory as 
function of age-related reduction of dopamine activity renders the significance of 
dopamine in motor control, cognitive control and executive function (Volkow, Gur, et al., 
1998).  
The influence of dopamine on motor control, sensorimotor integration and motor learning 
suggests itself due to the predominant expression of dopamine in nuclei of the basal 
ganglia (Smith and Kieval, 2000). This structure is essentially involved in motor and 
oculomotor movement and connects with thalamic and prefrontal structures and provides 
the means to act as a selective gatekeeper for motor and cognitive programmes (Mink, 
1996; Hayes et al., 1998; van Schouwenburg, Aarts and Cools, 2010). Such selection 
processes include essential components of cognitive control, namely the suppression of 
inappropriate response, simultaneously with the selection of appropriate alternatives 
(Cools, 2008).  
Several theories focus on the functional role of dopamine in learning and motivation 
based on the well-established observation of phasic release of dopamine to rewarding 
stimuli. Empirical work has strengthened the reward-prediction theory which postulates 
facilitation of learning by scaling dopamine release to the discrepancies between 
predicted and actual outcome (Cagniard et al., 2006; Schultz, 2007). Accordingly, 
dopamine integrates motivational and learning processes to form an adaptive behavioural 
system (for detailed review of dopamine and learning and motivation, see R. A. Wise, 
2004).  
In short, the influence on motor control and motivation implicates that dopamine plays a 
key role in the adjustment of behavioural control mechanisms. This fine-tuning can be 
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distorted by drugs inducing dopamine release. Consequences can be euphoric feelings of 
well-being and heightened arousal and attention, but also self-destroying drug seeking or 
compulsive behaviour (Nutt et al., 2015). Other examples of dysfunctional dopamine 
system and maladaptive behaviour is observed in obsessive compulsive disorder, 
schizophrenia, attention-deficit disorder or Parkinson’s disease (Nieoullon, 2002; Koob 
and Volkow, 2016). Better understanding of these delicate tuning mechanisms on 
cognition applied by dopamine can help to interrupt or prevent the development of 
maladaptive behavioural strategies.  
4.1.1 Dopamine Systems 
The most prominent dopaminergic axonal projections are located in the mesencephalon 
forming several major dopaminergic pathways. Originally three different cell groups 
were classified based on their location: the ventral tegmental area (A10), substantia nigra 
pars compacta (A9) and the retrorubral area (A8) (Dahlström and Fuxe, 1964). These 
nuclei give rise to the mesolimbic, the mesocortical (A8 and A10) and the mesostriatal 
(nigrostriatal, A9) pathways (Figure 1). The mesolimbic pathway projects to the limbic 
striatum (nucleus accumbens) and the olfactory tubercle (Björklund and Lindvall, 2011) 
and is involved in motivation, emotion and reward (Wise and Bozarth, 1987; Nader, 
Bechara and van der Kooy, 1997). The mesocortical dopamine neurons project to the 
cingulate, entorhinal and medial prefrontal cortex and are involved in executive function, 
such as working memory and other higher cognitive processes (Le Moal and Simon, 
1991). The mesostriatal pathway is topographically organized that medial cells of the 
substantia nigra pars compacta and the retrorubral area project ventrally to the nucleus 
accumbens and the ventral striatum, whereas more lateral located cells yield projections 
to the dorsal striatum forming the nigrostriatal pathway. The nigrostriatal pathway or 
nigrostriatal bundle, innervates areas that control motor behaviour in basal ganglia, such 
as caudate and putamen (Ungerstedt, 1971; Björklund and Lindvall, 2011). The 
tuberoinfundibular dopamine system projects from the hypothalamus to the anterior 
pituitary gland and controls prolactin secretion (Iversen et al., 2010).  
The successful treatment of striatal dopamine deficits in Parkinson’s disease with 
dopaminergic agonists drove early research focus of dopamine towards motor control 
(Bernheimer and Hornykiewicz, 1965). The discovery of the mesocortical dopamine 
system by Thierry and colleagues (Thierry et al., 1973; Berger et al., 1974) in the mid-
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1970s entailed a plethora of data on the functional role of dopamine in the prefrontal 
cortex and its role in cognition.  
The anatomical layout permit dopamine a modulatory role on behaviour, specifically the 
adaptation of action and emotion (Nieoullon, 2002; Nieoullon and Coquerel, 2003). 
Additionally, dopamine is more abundant in frontal cortex than posterior parts of the brain 
(Nieoullon, 2002) which indicates functional correlates in higher-order cognition (Frith 
and Dolan, 1996; Miller and Wallis, 2010). Adaptive behaviour demands motivational 
and goal-directed processes which have been associated with limbic-striatal and fronto-
striatal structures, respectively (Cools, 2008). Recent research has moved from the simple 
separation between nigral and ventral tegmental of dopamine projections to discrete 
forebrain targets to a more complex represenation of dopamine neuron subtypes 
expressed by variations in morphological features, co-transmitters and marker proteins 
(Björklund and Dunnett, 2007).  
4.1.2 Dopamine Life Cycle 
The amino-acid tyrosine is the precursor for the synthesis of dopamine, as well as 
norepinephrine and epinephrine and contains the chemical structure catechol. The catalyst 
Figure 1. Dopamine Pathways.  
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for catecholamine synthesis is the enzyme tyrosine hydroxylase which turns the rate-
limiting enzyme tyrosine to dopa. The enzyme dopa L-amino acid decarboxylase removes 
a carboxyl group yielding dopamine. The amount of dopa available determines the 
amount of dopamine synthesized (Figure 2A). Although dopamine qualifies as a 
neurotransmitter, further synthesis changes dopamine to norepinephrine also known as 
noradrenaline by dopamine beta-hydroxylase (in vesicles). Epinephrine is synthesized by 
phentolamine-N-methyltransferase acting on norepinephrine.  
For example, in response to behavioural stimuli, dopamine is released from vesicles into 
the synaptic cleft, extrasynaptic dopamine level rises to a plateau and interacts with 
postsynaptic receptors. Dopamine receptors are divided into D1-like (D1, D5) and D2-
like (D2, D3, D4) subgroups (for a detailed review see: Beaulieu & Gainetdinov, 2011). 
The subdivision is based on G-protein coupling (Vallone, Picetti and Borrelli, 2000). 
After reaching the plateau, dopamine levels slowly return to baseline through different 
routes, namely diffusion, reuptake and degradation (Chen and Reith, 2000; Wayment, 
Schenk and Sorg, 2001; Cragg and Rice, 2004; Rodriguez et al., 2013). Released 
dopamine is catabolised by catechol-O-methyl transferase (COMT) and monoamine 
oxidase (MAO) or more effectively taken back into the axon terminal via Na+-dependent 
cell membrane transporters and packed back into vesicles through vesicular monoamine 
transporters or metabolized via MAO (Figure 2B). The primary mechanism of dopamine 
clearance vary amongst brain areas. Inhibition of norepinephrine transporters and MAO 
in prefrontal cortex prolongs extracellular dopamine levels two- to four fold. In mice 
lacking the COMT mechanism, prolongation is doubled, whereas a lack of dopamine 
transporters did not influence prefrontal extracellular dopamine levels (Wayment, Schenk 
and Sorg, 2001; Käenmäki et al., 2010). In contrast, dopamine transporters are 
responsible for 95% of dopamine uptake in the striatum and play a crucial role in the 
maintenance of presynaptic dopamine storage, whereas in the hippocampus the 
norepinephrine transporter is the primary route of dopamine uptake (Cass et al., 1993; 
Gainetdinov et al., 1998; Borgkvist et al., 2011). 
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Reuptake differentiates catecholamines from neurotransmitters such as acetylcholine and 
makes the neurotransmitter system sensitive to prolongation of synapse action. To gain 
further understanding of the specificity of dopamine innervations and the effects on 
cognitive and behavioural function, these mechanisms are useful targets of specific 
dopaminergic modulation. For example, substances acting on transporters can influence 
brain function and offers therapeutic opportunities.  
4.2 Dopamine Transporter  
The time course of dopamine transmission is tightly regulated by termination 
mechanisms. By challenging reuptake or degradation processes with a range of 
pharmacological tools it is possible to stimulate dopaminergic neurons (Wayment, 
Schenk and Sorg, 2001; Cragg and Rice, 2004; Käenmäki et al., 2010). Majorly, in striatal 
Figure 2. Dopamine Synthesis and Synaptic Transmission 
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regions the dopamine transporter regulates transmission by recycling extracellular 
dopamine back into the pre-synapse. Therefore, this structure offers an opportunity to 
specifically target striatal dopamine effects and allows to further examine the reciprocal 
projections from striatum to the prefrontal cortex during cognition.  
The following paragraphs only briefly describe dopamine transporter structure and 
function, a more detailed description would be beyond the scope of the current work (for 
detailed information see: Chen & Reith, 2000; Gowrishankar, Hahn, & Blakely, 2014). 
4.2.1 Structure and Localization 
The dopamine transporter is expressed exclusively in dopaminergic neurons within the 
central nervous system. Peripherally, the protein is found in stomach, pancreas and 
kidney. The highest expression is found in midbrain neurons originating in the substantia 
nigra and ventral tegmental area. Within the midbrain the expression is maximal at caudal, 
ventral and lateral groups of dopamine neurons and decreases medially in the ventral 
tegmental areas (González-Hernández et al., 2004). Lower dopamine transporter amounts 
are found in cortex, amygdala and hypothalamus. 
From a developmental perspective dopamine transporters appear at later stages, after 
embryonic midbrain neurons express tyrosine hydroxylase and synthesize dopamine. At 
this stage dopamine release is already established (Gainetdinov et al., 1998).  
At the cellular level the dopamine transporter is localized in the plasma membrane of 
neuronal perikary, dendrites, axons, synaptic terminals, and tubulovesicular intracellular 
structures (Nirenberg et al., 1996, 1997; Ciliax et al., 1999). The dopamine transporter 
belongs to the family of SLC6A Na+/Cl—dependent transporters which also encompass 
the serotonin and norepinephrine transporters (Giros et al., 1992; Chen, Reith and Quick, 
2004). In the midbrain it is the main regulator of dopamine signal termination 
(Gainetdinov et al., 1998). The uptake of extraneuronal dopamine terminates dopamine 
action at pre- and post-synaptic sites, followed by re-entering of dopamine into synaptic 
vesicles through vesicular monoamine transporters (VMAT) and storage until its next 
release. Reuptake mechanisms are very effective and characteristic for the regulation of 
dopaminergic signalling and homeostasis (Chen and Reith, 2000; Cheng and Bahar, 
2015).  
As described above, the density of dopamine transporters varies among different 
dopamine cell groups which suggest that differential amount of dopamine transporters 
Theoretical Framework: Dopamine Transporter 
14 
indicates differences in dopamine signalling in given anatomical regions, e.g. classical 
synaptic signalling or more volume transmission type signalling (Gainetdinov et al., 
1998). Further, due to their high binding potential with diverse pharmacological agents, 
dopamine transporters are commonly used as specific markers for dopaminergic neurons 
(Gainetdinov et al., 1998; Uhl, 2003). Thus, dopamine transporter availability or genetic 
markers of the dopamine transporter offer an opportunity to index dopamine neurons and 
dopamine activity (Costa et al., 2011; Volkow et al., 2015) which has resulted in 
considerable research interest in this transporter and its influence on cognition and 
behaviour.  
4.2.2 Synaptic Adaption and Dopamine Transmission 
Considerable evidence on the crucial role of the transporter in dopamine transmission and 
its molecular impact comes from studies with mice lacking dopamine transporters (Giros 
et al., 1996). Giros et al (1996) developed a strain of mice without the dopamine 
transporter gene (DAT KO mice). Behavioural consequences include abnormal dietary 
habits (slow weight gain), high locomotor activity, difficulty in adapting to novel stimuli 
accompanied with inflexible behaviour and a tendency to react more aggressive in 
stressful situations (Gainetdinov, 1999; Spielewoy et al., 2000; Sora et al., 2001).  
Further, the deletion of the dopamine transporter gene results in cellular adaptation to a 
hyperdopaminergic state, namely increased extracellular dopamine concentration, 
decreased neuronal dopamine receptors and decreased tyrosine hydroxylase 
phosphorylation (Giros et al., 1996; Jaber et al., 1996, 1997; Salvatore, Calipari and 
Jones, 2016). These alterations of dopaminergic pathways are already apparent in 
dopamine transporter deficient mice with 50% reduced dopamine transporter density.  
Amplitude of phasic dopamine release reaches a mere 6.8% in DAT KO mice compared 
to normal animals and the enzyme tyrosine hydroxylase is decreased by 74-90% in 
terminal fields of striatum and nucleus accumbens. Intracellular dopamine levels are 
reduced by 95% despite an increase of dopamine synthesis. Specifically in dorsal striatum 
compared to mesolimbic areas, dopamine release and tissue content of dopamine in DAT 
KO mice is strongly dependent on dopamine synthesis, indicating the importance of 
dopamine transporter to replenish intracellular stores of dopamine and to sustain 
dopamine release (Giros et al., 1996; Gainetdinov et al., 1998; Jones et al., 1998; 
Salvatore, Calipari and Jones, 2016). Furthermore, the clearance of extracellular 
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dopamine is prolonged by the factor 100 compared to wild type mice (Gainetdinov et al., 
1998). This hyperdopaminergic state during tonic signalling which is 5-times higher than 
in wild-type mice (Jones et al., 1998), has been linked to the hyperactive symptoms in 
DAT KO mice and gave rise to the animal model for ADHD (Gainetdinov and Caron, 
2001). Indeed, reduced striatal binding for a specific dopamine transporter radio tracer 
[123I]FP-CIT was observed in patients with ADHD which strengthened the link between 
a hyperdopaminergic state with hyperactivity symptoms (Hesse et al., 2009).  
An artificial augmentation of dopamine transporters in another strain of mutant mice leads 
to a hypodopaminergic state, namely 40% reduction in the concentration of extracellular 
dopamine and cellular adaptation including a 50% increase of dopamine transporter 
activity and upregulation of postsynaptic dopamine receptors (Salahpour et al., 2008; 
Ghisi et al., 2009; Calipari and Jones, 2014). Behaviourally, these mutant animals display 
higher sensitivity to drug-induced reward and psychomotor properties to amphetamine, 
but no effects on basal locomotor properties, even after blockage of dopamine transporter 
with, e.g. methylphenidate (Salahpour et al., 2008).  
In normal animals, dopamine transporter activity indirectly modulates phasic signalling 
which is triggered by reward and sensory signals and plays a crucial role in learning 
mechanisms (Schultz, 2007). Dopamine release in DAT KO mice is not sufficient to 
evoke phasic extracellular increase over the basal dopamine level sustained by the altered 
tonic activity which offers an explanation for observed spatial cognitive deficits and 
difficulties in suppressing inappropriate responses and selection of salient stimuli 
(Benoit-Marand, Jaber and Gonon, 2000). Interestingly, a summary of study results on 
extracellular dopamine in gene-modified mice, shows that both reduced and increased 
expression of dopamine transporters lower the peak concentration of extracellular 
dopamine in response to pulse stimulation compared to wild-type controls (Figure 7A, 
Best, Nijhout, & Reed, 2009). This indicates that dopamine release is not strictly 
proportional to dopamine transporter density and further reveals regulatory mechanisms 
for transient dopamine release after consecutive bursts. Furthermore, Cragg and Rice 
(2004) argue that dopamine clearance, specifically during burst firing, depends more on 
diffusion rather than rapid uptake and the influence of dopamine transporter is seen in the 
extended lifetime and augmented net concentration of extrasynaptic dopamine. 
Nonetheless, there is converging evidence that the rate of dopamine uptake influences 
intracellular dopamine quantity available for stimulated release, thus the dopamine 
transporter is an important factor modulating dopaminergic tone (Ferris et al., 2014). 
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Taken together, molecular differences in the expression of the dopamine transporter 
impact dopamine release and therefore dopaminergic transmission. Deficiency or the 
absence of the dopamine transporter translates to impaired selection of salient stimuli and 
impeded control over inappropriate responses (Benoit-Marand, Jaber and Gonon, 2000). 
This suggests dopamine transporter characteristics can be predictive of behavioural 
control (Meiergerd, Patterson and Schenk, 1993; Parsons, Schad and Justice, 1993; Cass 
and Gerhardt, 1994).  
4.2.3 Genetics 
The dopamine transporter gene exhibits a remarkable level of cellular specificity with the 
most robust expression in midbrain dopamine neurons (Bannon et al., 2001). The gene in 
humans encoding the dopamine transporter is the SLC6A3 gene located at chromosome 
5p15.3 (Giros et al., 1992; Vandenbergh et al., 1992). Within the 3' untranslated (UTR) 
region of the dopamine transporter gene lies a variable number of tandem repeat (VNTR) 
of a forty base pair (bp) sequence which is one of the most studied genetic variants of the 
dopamine transporter and will be the focus of this section (Vandenbergh et al., 1992; 
Swanson et al., 2000; VanNess, Owens and Kilts, 2005; Volkow, Wang, Newcorn, et al., 
2007; Kieling et al., 2010). The VNTR sequence ranges from three to 13 (Vandenbergh 
et al., 1992; Kang, Palmatier and Kidd, 1999), with the nine-repeat (9R or 440 bp) and 
the ten-repeat (10R or 480bp) alleles being the most common variants (Vandenbergh et 
al., 1992; Bannon, 2005).  
The functional effect has been investigated intensely yielding disparate findings. Some 
studies reported enhanced transcription of the reporter construct with nine-repeat 
sequence (Michelhaugh et al., 2001), others reported this for the ten-repeat vector (Fuke 
et al., 2001), whereas others found neither sequence affect the transcription rate 
(Greenwood and Kelsoe, 2003).  
In vivo imaging has provided similar inconsistent results. Higher striatal dopamine 
transporter availability was observed for nine-repeat allele carriers (van Dyck et al., 2005; 
van de Giessen et al., 2009), but others found the opposite, namely reduced amount of 
dopamine transporters in nine-repeat carriers (Heinz et al., 2000) compared with ten-
repeat homozygotes and another group failed to detect any association between the VNTR 
and dopamine transporter density (Martinez et al., 2001). Despite inconsistent findings, 
two independent meta-analyses concluded higher striatal dopamine transporter 
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availability in healthy human individuals for nine-repeat carriers with effect size of 
approximately g=.67 (Costa et al., 2011; Faraone et al., 2014).  
Furthermore, the VNTR polymorphism has been linked to ADHD (Coghill and 
Banaschewski, 2009; Franke et al., 2012). ADHD appears to have a strong heritable 
component (Gillis et al., 1992) and therapeutic effects are achieved with dopamine 
transporter ligands (methylphenidate and amphetamine). Although it is difficult to 
establish a robust link due to experimentally confounding factors such as clinical 
heterogeneity, comorbidity, interfering symptoms, and long-term medication between 
genotype and neurotransmission in patient studies (Berto et al., 2000; Koren, 2003), the 
ten-repeat allele has been coined a ‘high-risk’ allele for ADHD (Gizer, Ficks and 
Waldman, 2009). Further, there has been evidence that ten-repeat homozygous carriers 
show weaker treatment response (Winsberg and Comings, 1991; Kambeitz, Romanos and 
Ettinger, 2014) and impulsive behaviour in non-clinical samples (Mata et al., 2012). 
Meta-analyses have not confirmed a direct link between this polymorphism and 
behavioural measures of cognitive function in healthy subjects and patients with ADHD 
(Rommelse et al., 2008; Ettinger, Merten and Kambeitz, 2016). On the other hand, 
neuroimaging studies support the influence of the VNTR and cognitive function, 
including working memory (Bertolino et al., 2006; Caldú et al., 2007; Stollstorff et al., 
2010; Brown et al., 2011; Gordon et al., 2012; Wittmann et al., 2013), emotion processing 
(Taurisano et al., 2013; Bergman et al., 2014), reward sensitivity (Yacubian et al., 2007; 
Dreher et al., 2009; Franklin et al., 2009; Hahn et al., 2011) and inhibitory control, even 
in the absence of behavioural effects.  
Despite disparate findings, there is valid evidence from animal, pharmacological and 
neuroimaging studies that indicate a functional role for the polymorphism in the 
regulation of the dopamine transporter (Rao, Sorkin and Zahniser, 2013; Rajala et al., 
2014) and the modulation of mental operations in various cognitive domains (Garcia-
Garcia et al., 2010; van Schouwenburg, Aarts and Cools, 2010; Cummins et al., 2012; 
Sambataro et al., 2015).  
4.2.4 Ligands 
Intense investigation of the dopamine transporter is due to the high potency for various 
pharmacological agents. The dopamine transporter is the target of drugs of abuse such as 
cocaine and many therapeutic agents used to treat depression and ADHD. The inhibition 
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of dopamine transporter correlates with drug reinforcement and suggests a role of the 
dopamine transporter in substance abuse and addiction (Ritz et al., 1987). Ligands for the 
dopamine transporter include amphetamine and methamphetamine (substrates), and 
blockers like cocaine and methylphenidate (inhibitor). The continuous administration of 
substrates evokes a downregulation of transporter activity, followed by internalization of 
the transporter. For example amphetamine and related substrates increase extracellular 
dopamine by promoting reverse transport (Gainetdinov and Caron, 2003). In contrast, 
inhibitors, such as methylphenidate, indirectly impact the rate of dopamine release by 
blockage of dopamine transporters (Pucak and Grace, 1994; Leonard et al., 2004) and 
hinder, therefore, the reuptake of extracellular dopamine, specifically during phasic 
transmission (Wall, Gu and Rudnick, 1995) (Figure 2C & D). One of the most common 
ligands is methylphenidate, a catecholamine transporter inhibitor that also blocks 
norepinephrine transporter (Hannestad et al., 2010) and the first-choice treatment for 
ADHD with a large effect size (g=.8-1.0) (Banaschewski et al., 2006; Faraone and 
Buitelaar, 2010).  
The pharmacokinetics of methylphenidate are widely studied and resemble those of 
cocaine, amphetamine and methamphetamine (Kallman and Isaac, 1975; Ritz et al., 1987; 
Patrick and Markowitz, 1997; Huss and Lehmkuhl, 2002).  
Weight-adjust oral dosage of methylphenidate (0.3 to 0.6 mg/kg) is thought to block 
approximately 50% of dopamine transporters in healthy adults and therefore prolong 
stimulation of postsynaptic receptors due to increased intrasynaptical dopamine level 
(Volkow et al., 1995, 2001; Volkow, Wang, et al., 1998). A very common observation is 
a dosage-dependent effect on behaviour of dopaminergic agonists which also holds for 
methylphenidate. Low doses can reduce locomotor activity and distractibility, but at too 
high doses it causes an overwrought state of the central nervous system (Seeman and 
Madras, 2002). 
Simulation of uptake inhibition in dopamine cell transmission shows that basal dopamine 
level increases linearly and additionally at a certain level of dopamine transporter 
blockage a decoupling of postsynaptic receptors from pauses of phasic firing patterns 
takes place, i.e. receptors become tonically active regardless of firing pattern (Dreyer and 
Hounsgaard, 2012). In other words, dopamine receptors are less sensitive to pauses in 
dopamine cell firing at a critical level of uptake inhibition. The differential consequences 
of this dose-dependent effect become clear in single cell-recordings of dopamine neurons 
in the ventral tegmental area which show opposing effects of dopamine transporter 
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blockage with methylphenidate on firing rates. Besides a dose-dependent linear increase 
of responsive neurons, results show that with lower dosage (0.6mg/kg) the majority of 
neurons decreased their firing rate, whereas at higher dosage (2.5 and 10.0mg/kg) mainly 
an increase of firing rate was observed (Jones and Dafny, 2015).  
Thus, the qualitative effect of dopamine transporter inhibition depends strongly on the 
level of blockage and the basal dopamine activity (see 4.2.2). Volkow and colleagues 
(Volkow et al., 2001) describe the relation between dopamine transporter blockage and 
dopamine release as follows: “for an equivalent level of dopamine transporter blockage, 
methylphenidate would be more potent in a subject whose baseline release of dopamine 
is high than in a subject whose baseline release is low” (p. 4). This suggests that 
methylphenidate is more effective in subjects with higher dopamine transporter density 
which can be explained by the generally higher dopamine release in these subjects and 
serves as an ideal compound to target specific dopaminergic function. This dovetails with 
current findings of the same research group which demonstrate a positive correlation of 
dopamine transporter density and dopamine release in a healthy control group (Volkow 
et al., 2015).  
A recent review of single dose studies in healthy adults underlines the importance of 
dosage and lists precognitive effects of methylphenidate for working memory, processing 
speed, verbal learning, memory, attention and inhibition (Linssen et al., 2014; see 6.2.1).  
4.3 Goal of Dissertation 
The dopamine transporter modulates extracellular dopamine level and governs frequency 
and amplitude of firing patterns (Floresco et al., 2003; Cagniard et al., 2006). The current 
thesis employs knowledge from animal and pharmacological studies to gather 
information on the specificity of dopamine transporter effects on neural operations during 
cognitive function in healthy human subjects. In contrast to behavioural effects, 
neuroimaging data provide a more sensitive measure of genetic and pharmaceutical 
variation on cognition (Honey and Bullmore, 2004; Greene et al., 2008). Thus, in a 
multimodal imaging approach, dopamine transporter specific effects on cognition were 
examined.  
The experimental section consists of three empirical studies addressing the relationship 
of the dopamine transporter with cognition and brain function: (1) the association between 
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a dopamine transporter genotype and cognition, personality and brain function, (2) the 
role of the dopamine transporter genotype in predicting effects of the dopamine 
transporter-blocking compound methylphenidate, and (3) the effects of methylphenidate 
on brain function in comparison to another compound known to indirectly increase 
dopamine levels, viz. nicotine.  
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5. Methods 
Neuroimaging methods allow the examination of neural activity as a function of different 
dopamine transporter markers in relation to cognition in healthy humans (Cropley et al., 
2006). The following section gives an overview of methods used in identifying genetic 
and molecular markers in the adjacent empirical work as well as detailed information on 
functional magnetic resonance imaging.  
5.1 Functional Magnetic Resonance Imaging (fMRI) 
5.1.1 Basic Physical Principles 
Functional magnetic resonance imaging is a non-invasive method to measure brain 
activity. The signal represents the behaviour of hydrogen proton spin measured with 
magnetic resonance imaging (Logothetis et al., 2001). The protons either align parallel or 
anti-parallel to an externally applied strong magnetic field B0 (common field strength in 
human studies 1.5 to 3 Tesla). A majority of protons will align parallel, the lower 
energetic state. Although the surplus of parallel aligned protons is very small, this leads 
to a net magnetization oriented parallel to the magnetic field B0 (net magnetization 
vector). This net magnetization vector is tipped out of its equilibrium position with a radio 
frequency pulse applied perpendicular to the B0 and an amplitude B1 matching the 
precession frequency of the protons. The precession frequency is given by Larmor-
frequency (w), defined by the magnetic field strength B0 and the gyromagnetic ratio (γ) 
which is a fixed parameter for each nucleus type:  
𝑤 = 𝐵0 ∗ 𝛾  
The radio frequency pulse causes the protons to absorb energy and tilts the magnetization 
vector from the horizontal plane (dimension z) to the transversal plane (xy). Additionally, 
the precession of the spins are caused to rotate in phase. The frequency emitted by the 
transversely rotating magnetization vector can be measured with a receiver coil placed 
around the head. The transverse magnetization decays quickly, which is described as 
relaxation. The dipoles strive back to a lower energy state aligned with B0 and release 
their energy (longitudinal relaxation or spin-lattice relaxation). This process is described 
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by a time-constant T1 (time it takes for 63% recovery of magnetization along the z-axis). 
The time-constant T2 describes the time it takes for 37% of the transversal magnetization 
(xy plane) to decay (spin-spin relaxation). The latter occurs, because protons influence 
each other and lose their in-phase rotation. Static field inhomogeneity leads to a faster 
transversal relaxation as predicted by T2
*. In order to acquire images, this technique uses 
the relaxation processes, which are differentially fast depending on the tissue. Thus 
different tissues are visible as different contrast in images. For the spatial reconstruction 
field gradients are applied to B0 which allows to specifically excite only small slice to 
tissue with a radio frequency pulse of a given frequency. The individual signals 
corresponding to the spatial positions along the axes, are then decoded using Fourier 
Transformation. The time between two radio frequency pulses is called repetition time 
(TR); the time between excitation and measurement is called echo time (TE). These 
parameters are chosen to determine the influence of the time-constants on the image 
contrast. All the presented studies used gradient-echo EPI sequences which are very fast 
and efficient in tracking hemodynamic response (Logothetis, 2008). 
5.1.2 Haemodynamic Response in fMRI 
In order to investigate cognitive processes and the influence of dopamine on brain 
function and cognition, a correlate of brain activity is necessary. Functional magnetic 
resonance imaging (fMRI) makes use of the blood-oxygen-level-dependent (BOLD) 
contrast. Oxygenated blood, oxyhaemoglobin (Hb), is diamagnetic and enhances the 
signal. In contrast deoxyhaemoglobin (dHB) is paramagnetic and produces field 
distortions with lower signal. Local increase in blood oxygenation is linked to neural 
activity and glucose metabolism. Vascular changes allow oxygen extraction from the 
blood and therefore an increase of regional blood flow, blood volume and blood velocity 
(for details see Ances et al., 2008). During neural activity more oxygen is need and 
extracted from the blood, this is accompanied by a local excess in blood oxygen and 
produces a better BOLD signal. This increased BOLD signal occurs with a latency of 
three to six seconds after the onset of neural activity, but varies depending on task and 
brain regions (for details see Heeger & Ress, 2002). FMRI excels due to its high spatial 
resolution, but has a rather poor temporal resolution compared to for example 
electroencephalography, due to the hemodynamic delay.  
Characteristic for the BOLD signal in response to a stimulus is a specific temporal profile 
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which needs to be kept in mind during planning and analysing an fMRI study. The time 
lag between energy consumption and oxygen supply delays the actual BOLD response 
and is described as “initial dip”. After four to six seconds the response reaches the peak 
and further 30 seconds are necessary for the signal to regain the baseline state. This is 
especially important to consider when timing experimental events and the repetition of 
events within one category of interest.  
BOLD signal does not correlate perfectly with neurons’ firing rate, but there seems to be 
a strong link with pre-synaptic activity and secondary with action potentials rather than 
output signals in a given brain region (Logothetis and Wandell, 2004; Logothetis, 2008). 
Though, it is important to note that the mechanisms are more complex and not only arise 
from increase in firing of task sensitive neurons, but also from an interplay between 
excitatory and inhibitory neuronal communication (Logothetis, 2008). Nevertheless, 
keeping in mind the natural restrictions, today BOLD fMRI is a powerful tool to bridge 
the gap between neuronal correlates and cognitive processes (for extensive reviews see: 
Cabeza & Nyberg, 2000; Niendam et al., 2012). This method allows the observation of 
differential activation and localization of cognition-relevant brain areas according to 
experimental, e.g. genetic or pharmaceutical, conditions.  
5.1.3 Pharmacological fMRI 
Pharmacological fMRI is defined as a measure of “the direct modulation of regional brain 
activity by drugs that act within the central nervous system (CNS) or the indirect 
modulation of regional brain activity through pharmacologically modified afferent input.” 
(Wise and Tracey, 2006). This technique offers the opportunity to investigate drug action 
on brain systems, but also to develop measures of local drug effects (Stein, 2001). In the 
current work pharmacological fMRI is used as a neuroscientific tool to probe healthy 
brain function and to understand the contribution of neurotransmitter systems during 
cognition (Wise and Tracey, 2006). It is important to note that BOLD does not directly 
reflect molecular drug action, but given an appropriate design and experimental control, 
inferences can be drawn about substance effects on receptor systems and its behavioural 
correlates. The pharmacological modulation of task-induced BOLD is the approach most 
commonly used in human studies (Honey and Bullmore, 2004; Wise and Tracey, 2006). 
Substances can change task-induced activity either by changing neurovascular coupling 
or by modifying stimulus-induced neuronal activity without changes in neurovascular 
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coupling (Iannetti and Wise, 2007). Methylphenidate, for example, does not alter neural-
hemodynamic coupling (Rao et al., 2000; Mehta and Daly, 2011), therefore observed 
changes in brain activity or information processing are related to dopaminergic neuronal 
activity and not to changes in vasculature.  
Another caveat is the interpretation of stimulant-induced BOLD increases or decreases. 
As for example, dopaminergic induced reduction of BOLD in anesthetized monkeys has 
been accompanied by increased energy metabolism, indicating that observed BOLD 
activation does not directly reflect neural response (Zaldivar et al., 2014). Additionally 
direct injection of dopamine in visual cortex did not alter activation in this local area, but 
suggests that dopaminergic neuromodulation are effects demanding neuronal long-range 
interactions in dopaminergic circuits. Consequently, the site of action for dopaminergic 
compounds is not necessary the site of BOLD activation and modulation takes place 
through downstream receptor modulation.  
5.1.4 Preprocessing and Analysis of fMRI Data 
Detailed description of fMRI analysis can be found in several textbooks (Penny et al., 
2011; Poldrack, Mumford and Nichols, 2011; Huettel, Song and McCarthy, 2014), here 
the classical processing steps for acquired images are only explained in brief.  
Imaging data is preprocessed before statistical analyses are applied with the main goal to 
reduce unsystematic noise components. Traditionally a series of t images is recorded with 
each image consisting of v voxels (cuboid pixel). The first step in data pre-processing is 
the realignment of images of the series to one reference image (first or mean image). With 
rigid body transformation and the six motion directions (translation and rotation 
movement in three spatial dimensions) the motion parameters are calculated (dimensions: 
x, y, z in mm; rotation: pitch, roll, and yaw in degrees). Obtained parameters describe 
small movements and can be used in a later step to reduce motion related noise in the 
model (Brett, Johnsrude and Owen, 2002). To improve normalization to a standard 
template, it is recommended to co-register functional images to an anatomical, higher 
resolution image of the same scanning session. Depending on the sequence of slice 
acquisition and the design, it is necessary to perform a slice-time correction and 
compensate for sampling of slices at different time-points. The next step transforms 
individual brain images in a common space. During spatial normalisation individual 
brain structures are warped until they correspond to structures of a standard brain. The 
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classical template was provided by Talairach and Tournoux (Talairach and Tournoux, 
1988), but more recent studies use a template created by the Montreal Neurological 
Institute (MNI). The final step to decrease measurement noise includes spatial smoothing 
with a Gaussian kernel. This allows reduction of sensitivity for false positive results 
(Aguirre, 2006).  
In order to identify voxel’s time-series in which the signal is significantly higher than the 
noise, a General Linear Model (GLM) is applied to the preprocessed images (K. J. Friston 
et al., 1995; Karl J Friston et al., 1995). For this experimental conditions are contrasted 
to a baseline condition. These experimental conditions can be blocked or occur as single 
events and subsequently serve as regressors in the model. For each voxel’s time-series 
(univariate analysis) the parameter estimate (β-value) describes the fit to the model. In 
brief, this model is expressed as:  
𝑦(𝑡) = 𝛽 ∗ 𝑥(𝑡) + 𝑐 + 𝑒(𝑡) 
The observed data corresponds to y(t), the experimental matrix with a vector of ones and 
zeros (presenting absence or presence of experimental stimulation) is described by x(t), c 
is a constant (e.g., baseline intensity) and e(t) represents the error. Additionally, the time-
series is convolved with the haemodynamic response function (HRF: temporal profile of 
the BOLD response see 3.1.2) to improve the fit of the model. At group-level, parameter 
estimates from individual subject GLMs are fed into a second-level GLM. This results in 
statistical parametric maps (SPM), displaying the improbability of their estimation (t-
values). From these second-level SPM one can identify voxels that are significantly 
activated during corresponding experimental condition. As last step, the multiple 
comparison problem deriving from the mass univariate approach has to be taken care of. 
This is done by adjusting the statistical thresholds as expressed by the p-value. In order 
to localize activated voxels within brain structures several anatomical atlases can be used 
(Brett, Johnsrude and Owen, 2002).  
5.2 Single Photon Emission Computed Tomography (SPECT) 
To investigate the role of dopamine transporter in human it is also possible to measure 
density via single photon emission tomography (SPECT). This technique combines 
nuclear medicine imaging technique and computer tomography. In contrast to fMRI, this 
is an invasive method and requires a chemical to enter the tissue and bind to the molecular 
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target. These ligands consist of either small molecules, peptides, proteins or antibodies 
and second of a label that can be identified by an imaging modality. For SPECT these 
ligands are called radiotracers or radiopharmaceuticals. Various pharmaceuticals are 
eligible as radiotracers for dopamine transporter. The most common 
radiopharmaceuticals are 123I-FP-CIT and 99mcTC-TRODAT-1 (Park, 2012; Shen, Liao 
and Tseng, 2012). Radiation detectors receive emitted gamma photons from the 
distributed radio-active pharmaceuticals similar to conventional nuclear medicine. 
However in contrast to conventional nuclear medicine methods, image reconstruction 
methods can generate a cross section image of the distributed radiopharmaceutical and 
create a more detailed representation of tissue properties (ALehyani, 2009).  
In the present work SPECT scans were obtained after injection of 123I-FP-CIT 
(DaTSCAN; GE Healthcare, Amersham,UK) using a Prism 3000 triple-headed gamma 
camera (Philips, formerly by Picker, Cleveland, OH, USA) equipped with high-resolution 
fan beam collimators (see also Costa et al., 2013). Analysis was performed by Prof La 
Fougère. Briefly, images were reconstructed by filtered back-projection and corrected for 
attenuation (Chang, 1978). Using a modified version of the Brain Analysis Software 
(BRASS, version 3.5; Hermes Medical Solutions) and standardized 3-D volumes of 
interest (VOIs), data were semi-quantitatively evaluated. This includes a multistep 
registration of individual images to an 18F-DMFP template for healthy controls (Mathias 
Schreckenberger, University of Mainz) and adjustment of VOIs by automatic 
registrations with six degrees of freedom. For each participant whole striatum, caudate 
and putamen were identified. An additional VOI was defined in the occipital cortex of 
the template image in order to calculate the specific binding with the following formula: 
(striatum-occipital cortex)/occipital cortex. Specific binding was therefore corrected for 
unspecific uptake in the occipital cortex.  
5.3 Candidate Gene Approach 
Human cognition and brain function is significantly heritable (Friedman et al., 2008; 
Greene et al., 2008; Frank and Fossella, 2011). Additionally, performance increase or 
decrease after administration of dopamine-releasing stimulant is baseline dependent 
(Mehta and Riedel, 2006) which suggests genetic predisposition in dopaminergic 
functioning that not only influences drug response, but is also evident in variability of 
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cognition and behaviour. To investigate genetic influence it is either possible to use 
candidate gene designs, or genome wide designs (Frank and Fossella, 2011; Montag and 
Reuter, 2014). While it is important to identify common genetic variants that underlie 
common psychiatric disorders with genome wide association studies (GWASs), it seems 
that reported associations are composed of small effects of many common variants 
(Purcell et al., 2009). In contrast, the candidate gene approach aims to investigate the 
influence of a specific gene on specific cognitive processes, or the contribution of the 
genes biochemical functionality on human mental operation (Frank and Fossella, 2011). 
Preferably, the genetic variant is associated with biochemical functionality as for example 
gene expression or protein synthesis. Critically, the associations are informed by previous 
literature on pharmacological or animal models linking the genetic polymorphism to 
protein function, synaptic characteristics or other molecular mechanisms and cognitive 
processes. For example, genetic variation in D2 receptor affinity determines direction of 
response to D2 agonist stimulation and is also predictive of learning and performance (for 
details see review by Frank & Fossella, 2011).  
The gene variants in the empirical studies of this thesis were determined in the laboratory 
of Prof Dan Rujescu at the University of Munich. DNA was extracted from 3ml saliva 
using QIAamp DNA Blood Midi Kit (Qiagen, Germany).  
5.3.1 SLC6A3 3´- UTR VNTR 
As mentioned in 4.2.3 a widely studied genetic variant of the dopamine transporter is the 
SLC6A3 3'-UTR VNTR polymorphism. The functional role of the VNTR has been 
investigated extensively in animal and human models and confirms an association 
between dopamine transporter availability and genetic variation (Costa et al., 2011; 
Faraone et al., 2014). Most common genetic variants are carriers with at least 9 repeat 
allele or two copies of the 10R allele. Subsequently, the genotype groups of 10 repeat 
homozygotes and 9 repeat heterozygotes became the primarily studied genetic variations. 
Less frequent variants such as the 9 repeat homozygotes are usually combined within the 
group of 9 repeat alleles or excluded (Ettinger, Merten and Kambeitz, 2016).  
For the SLC6A3 VNTR, the following primers were used: forward, 5´-TGT GGT GTA 
GGG AAC GGC CTG AG-3´, reverse: 5´-CTT CCT GGA GGT CAC GGC TCA AGG-
3´ (Vandenbergh et al., 1992). A PCR reaction containing 50ng DNA, 10pmol of each 
primer, 5U Taq polymerase (Fermentas, Vilnius, Lithuania), and 100mM dNTP Mix 
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(Fermentas) was carried out with buffer supplied by the manufacturer in a final volume 
of 20 ml. Amplification was carried out in a Thermocycler (Eppendorf, Hamburg, 
Germany) using the following conditions: initial denaturation at 95 1C for 5 min, 35 
cycles of denaturation at 95 1C for 30 s, annealing at 61 1C for 30 s, and elongation at 72 
1C for 90 sec following a final elongation at 72 1C for 3 min. PCR products were 
separated on 2% agarose gel by electrophoresis and visualized by ethidium bromide 
staining and UV fluorescence. 
5.3.2 COMT val158met 
In prefrontal cortex dopamine transporter is scarce (Ciliax et al., 1999), therefore other 
mechanisms influence dopaminergic signalling. A gene encoding the dopamine 
degrading enzyme catechol-O-methyltransferase (COMT) has been associated with 
prefrontal dopamine function (Winterer et al., 2006). A single nucleotide polymorphism 
(SNP) in this gene (reference sequence identification code rs4680) results in a valine-to-
methionine substitution at codon 158 (val158met) of the membrane-bound isoform of the 
protein. This allelic variation (also known as the val158met polymorphism) is functional, 
as the met158 allele has about one third to one fourth of the activity of the val158 allele, 
resulting in less efficient catecholamine catabolism. Less COMT activity (met allele) 
implies more dopamine in the synapse and therefore more action at postsynaptic 
receptors, whereas greater COMT activity (val allele) implies less intrasynaptic 
dopamine. (Lotta et al., 1995; Lachman et al., 1996; Weinshilboum, Otterness and 
Szumlanski, 1999). In the prefrontal cortex dopamine metabolism depends more readily 
on enzymatic degradation by COMT than on transport and reuptake by the dopamine 
transporter (Slifstein et al., 2008). In contrast, in striatum, COMT is scarce, and dopamine 
transporter predominantly terminate dopaminergic signalling (Gainetdinov & Caron, 
2003; see also 4.1.3.2). Hence, using both, SLC6A3 VNTR and COMT as genetic 
predictors of dopaminergic transmission, allows dissociation of striatal and prefrontal 
influence on cognitive processes. 
COMT rs4680 was genotyped using the MassARRAY platform (Sequenom, San Diego, 
CA) according to manufacturer's protocol. Briefly, PCR (ACG TTG GAT GTT TTC 
CAG GTC TGA CAA CGG and ACG TTG GAT GAC CCA GCG GAT GGT GGA 
TTT) and extension primers (ATGCACACCTTGTCCTTCA) were designed using the 
Assay Designer 4.0. 12,5ng of genomic DNA were used for Multiplex PCR reactions 
Methods: Candidate Gene Approach 
29 
with a mastermix containing 500µM dNTPs (ABgene, Hamburg, Germany), 100nM PCR 
primers, 1,625mM MgCl2 and 0,5U HotStar Taq polymerase (Qiagen, Hilden, Germany). 
Following SAP (shrimp alkaline phosphatase) treatment the iPLEX reaction cocktail 
containing extension primers (7-14µM), 1x iPLEX termination mix and 1x iPLEX 
enzyme was added to the PCR-products. After desalting the extension products with 
SpectroCLEAN resin, samples were spotted on SpecroCHIPs GenII and analysed with 
the MassARRAY MALDI-TOF mass spectrometer. Allele specific extension products 
and resulting genotypes were identified by Typer 3.4. 
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6. Experimental Section 
The following section presents an overview of three neuroimaging studies investigating 
the effects of dopamine on impulsivity, motor, and oculomotor control. The theoretical 
background of animal and patient literature has shown that dopaminergic activation is 
crucial in behavioural control (Cools, 2008). Failure in behavioural control leads to 
impulsive reactions mediated by impaired action restraint, action cancellation and failure 
of inhibitory processes (Bari and Robbins, 2013). The neural mechanisms of inhibitory 
control have been described in a number of previous functional neuroimaging studies 
(Aron, 2007; Simmonds, Pekar and Mostofsky, 2008; Bari and Robbins, 2013; Criaud 
and Boulinguez, 2013), making them ideally suited as well-characterised behavioural 
probes for the study of pharmacological and gene effects at the level of brain function. 
Therefore, the first two studies apply inhibitory and cognitive control paradigms, as wells 
as impulsivity measures in the investigation of genetic and molecular influence of the 
dopamine transporter on performance and neural activation. The third study operates on 
a pharmacological dissociation between dopamine transporter inhibitor and a cholinergic 
agonist, in an effort to disentangle dopamine transporter specific effects from another 
compound which excels dopaminergic enhancement second to stimulation of the 
cholinergic transmitter system.  
6.1 Summary Publication I 
Kasparbauer, A.-M., Merten, N., Aichert, D. S., Wöstmann, N., Meindl, T., Rujescu, D., 
& Ettinger, U. (2015). Association of COMT and SLC6A3 polymorphisms with 
impulsivity, response inhibition and brain function. Cortex, 71, 219–231. 
http://doi.org/10.1016/j.cortex.2015.07.002 (see Appendix A). 
 
Inhibitory control describes the ability to suppress inappropriate actions. Commonly used 
paradigms in research are response inhibition tasks in which participants supress motor 
action in the presence of a stop stimuli (Aron, 2009; Bari and Robbins, 2013). Stop-signal, 
go/no-go, Stroop or anti-saccade tasks demand suppression of a habituated response and 
require to behave flexibly by updating or overwriting planned motor responses. Active 
inhibition of a response has been linked to the prefrontal cortex, particular the right 
Experimental Section: Summary Publication I 
31 
inferior frontal cortex (Aron, Robbins and Poldrack, 2014). Additionally, subcortical 
structures such as the putamen and caudate have been associated with inhibitory control 
mechanisms (Frank, Loughry and O’Reilly, 2001; Frank and O’Reilly, 2006; Cools, 
2008; Aarts et al., 2010; Zandbelt and Vink, 2010; Costa et al., 2011; Costa, la Fougère, 
et al., 2013). Furthermore, there is evidence from neuropharmacological and 
neuroimaging studies implicating dopaminergic fronto-striatal networks in prepotent 
response inhibition, particularly as measured by go/no-go, stop-signal and antisaccade 
tasks (Aron, Dowson, Sahakian, & Robbins, 2003; Criaud & Boulinguez, 2013; Hutton 
& Ettinger, 2006; Munoz & Everling, 2004; Nandam et al., 2011; Nandam, Hester, & 
Bellgrove, 2014; Simmonds, Pekar, & Mostofsky, 2008). Behavioural genetic studies 
(Anokhin, Heath, & Myers, 2004; Macare, Meindl, Nenadic, Rujescu, & Ettinger, 2014) 
as well as research on patients with ADHD, obsessive-compulsive disorder, drug 
addiction, schizophrenia and their unaffected relatives suggests that a genetic 
predisposition underlies deficits in response inhibition (Aron & Poldrack, 2005; 
Chamberlain et al., 2007; Ersche et al., 2012; Raemaekers, Ramsey, Vink, van den 
Heuvel, & Kahn, 2006). Particularly a subdivision of the striatum, the sensorimotor 
striatum an area essential to motor planning and activity (Lappin et al., 2009), 
demonstrates a high heritability factor (Stokes et al., 2013)  
Consequently, genetic predisposition of frontal and striatal dopamine flux are potential 
predictors of inhibitory control performance and can further understanding of 
mechanisms contributing to impaired inhibition in patient population.  
6.1.1 SLC6A3 3'-UTR VNTR Polymorphism Cognition and Brain 
Function 
A genetic polymorphism of the dopamine transporter is a VNTR of the SLC6A3 gene 
located in the 3’ -UTR of the gene (4.2.3). The polymorphism has been scrutinized as 
potential predictor for attention, working memory, executive functions and long-term 
memory (Ettinger, Merten and Kambeitz, 2016). 
There is evidence of associations between the SLC6A3 3’-UTR VNTR polymorphism and 
hemodynamic response during various cognitive tasks in healthy humans. During 
working memory, carriers of two copies of the 10 repeat allele (10/10) show higher 
connectivity in the salience network and regions of the default mode network (Gordon et 
al., 2012) which was associated with higher subjective ratings of impulsivity. During 
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episodic memory formation 10/10 carriers showed lower right midbrain activation 
accompanied with lower learning rates and blunted response to error signals in ventral 
striatum (Schott et al., 2006). Further, regions with lower 10/10 BOLD activation 
included anterior cingulate, caudate, insula and cerebellum. 
Blunted striatal activity in 10/10 carriers to reward stimuli has been also observed by two 
other independent studies (Yacubian et al., 2007; Dreher et al., 2009). Others (Hahn et 
al., 2011) have found a positive correlation between reward sensitivity and reward-related 
activity in 10/10 carriers but not in 9R carriers. Franklin et al. (Franklin et al., 2009) found 
a positive correlation between ventral striatal activity and craving of smoking in 10/10 
smokers, but not in 9R smokers. In a different study, 10/10 carriers showed increased 
striatal activations for motivation compared to neutral cues, this was also observed during 
reward-predicting items (Wittmann et al., 2013). Genotype effects were also observed 
during verbal fluency which were expressed in increased activation for 10/10 carriers in 
left anterior insula and right caudate nucleus (Prata et al., 2009; Pauli et al., 2013).  
Despite overwhelming evidence of impaired inhibitory control, specifically response 
inhibition in patients with ADHD (Aron and Poldrack, 2005) and the improvement of 
symptoms after administration of a dopamine transporter inhibitor (Pasini et al., 2013), 
there is little investigation on the specificity of the dopamine transporter’s functional role 
in healthy human subjects during inhibition.  
Behavioural studies suggest homozygosity for the 10R allele to be linked to worse 
response inhibition (Cornish et al., 2005) and increased impulsive behaviour (Gizer, Ficks 
and Waldman, 2009; Mata et al., 2012). However, others found an opposing pattern with 
9R homozygotes performing worse in a Stroop task compared to 10/10 and 9/10 carriers 
(Schneider et al., 2014). 
A meta-analysis searching for an association between the dopamine transporter genotype 
SLC6A3 3’-UTR VNTR and different cognitive functions in healthy samples has failed 
to find significant results (Ettinger, Merten and Kambeitz, 2016). In contrast, 
neuroimaging studies report significant effects on hemodynamic response in absence of 
performance effects (Bertolino et al., 2009; Congdon et al., 2009; Colzato et al., 2010). 
Additionally, genetic imaging studies of adolescents during response inhibition revealed 
increased activation in frontal, medial and parietal regions in 10R carriers compared to 
non-10R carriers (Braet et al., 2011); the opposite was observed in adult ADHD patients 
(Dresler et al., 2010).  
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6.1.2 COMT val158met Polymorphism and Cognition and Brain 
Function 
The dopamine transporter is scarce in the cortex and therefore other mechanisms 
influence dopamine levels. For example COMT plays a particular role in dopamine flux 
in the prefrontal cortex and its mRNA expression is significantly higher in prefrontal 
structures compared to striatum (Matsumoto et al., 2003; Chen et al., 2004).  
Several studies have reported a COMT val158met (5.3.2) impact on executive function, 
working memory (Egan et al., 2001; Bishop et al., 2008) and attentional control (Blasi et 
al., 2005; Winterer et al., 2006). Generally, COMT impacts performance and processing 
of stable and flexible cognitive demands. Studies have revealed an advantage of the met 
allele across different tasks requiring both, maintenance and continuous updating of 
information, such as spatial working memory and cognitive control (Goldberg et al., 
2003; Diamond et al., 2004; Tan et al., 2007). For example in the Wisconsin Card Sorting 
Test, a task demanding intact prefrontal functioning, met allele carriers make fewer errors 
than val carriers (Egan et al., 2001). While the difference in prefrontal activity between 
met and val carriers seems relatively robust, an overall effect of COMT polymorphism is 
not clear and effects strongly depend on particular task demands (Meyer-Lindenberg et 
al., 2005; Tunbridge, Harrison and Weinberger, 2006; Barnett, Scoriels and Munafò, 
2008; Dickinson and Elvevåg, 2009). 
Evidence relating COMT to response inhibition and its neural correlates is inconsistent. 
Whilst there is evidence of the val allele being associated with better inhibition in the 
antisaccade task (Haraldsson et al., 2010), the met allele has been associated with better 
performance in the Stroop task (Schneider et al., 2014). Other studies have failed to 
observe significant associations with go/no-go and stop-signal task performance (Husain 
and Mehta, 2011; Stokes et al., 2011; Plewnia et al., 2013; Gurvich and Rossell, 2014). 
With regard to brain function, val carriers showed reduced prefrontal hemodynamic 
response in the prefrontal cortex compared to non-val carriers during antisaccades in an 
fMRI study (Ettinger et al., 2008). Similarly, Congdon and colleagues (2009) observed 
reduced BOLD activation in the right inferior frontal cortex in carriers of the val allele 
during successful inhibition in the stop-signal task. The opposite pattern was observed in 
the posterior cingulate cortex during a go/no-go task (Stokes et al., 2011).  
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6.1.3 Rational of the Study 
In brief, studies with negative findings at the level of inhibitory performance found 
associations between neural activation during inhibition and the COMT or SLC6A3 
polymorphisms (Ettinger et al., 2008; Congdon et al., 2009; Stokes et al., 2011), 
suggesting that the investigation of brain function may be a more powerful method for 
the detection of gene effects than the study of behavioural measures alone (Meyer-
Lindenberg and Weinberger, 2006; Greene et al., 2008).  
Neuroimaging studies combining the missense COMT val158met and the SLC6A3 3’-UTR 
VNTR polymorphism have found cumulative and functionally distinct effects. For 
example Schott et al. (2006) found an impact of COMT in right prefrontal cortex and 
occipital regions but not in the midbrain during episodic memory formation (Schott et al., 
2006). Whereas during working memory and motivational tasks a gene-gene interaction 
becomes apparent. During working memory, a cumulative effect expressed by blunted 
response in 10/10 and met/met carriers in prefrontal cortex was observed by two 
independent research groups (Bertolino et al., 2006; Caldú et al., 2007). Similarly, during 
reward sensitivity, 10/10 and met/met carriers showed reduced responsiveness in caudate 
and ventral striatum as well as lateral prefrontal cortex compared to 9R and met/met 
carriers (Yacubian et al., 2007; Dreher et al., 2009).  
Congdon and colleagues (Congdon et al., 2009) were the first to examine the 
neurophysiological influence of COMT and SLC6A3 3’-UTR VNTR polymorphism 
during response inhibition. Their sample consisted of 43 healthy participants; however, 
investigation of gene-gene interaction was not possible. The results showed an influence 
of the SLC6A3 3'-UTR VNTR in subthalamic nuclei and supplementary motor cortex 
activation. This effect was mediated by a blunted response in 10/10 carriers during 
successful stop trials. Whereas an influence of COMT was found in right inferior frontal 
cortex with greater activation of groups with met alleles as compared to val/val carriers 
during successful go and successful stop trials. In contrast, Cummins and colleagues 
(Cummins et al., 2012) did not find a modulation of brain activation with the dopamine 
transporter polymorphism during a similar stop-signal paradigm.  
In sum, it seems that both the 10/10 and the val allele are genetic variants associated with 
lower neural response during response inhibition, strengthening the concept that reduced 
dopaminergic signalling during inhibitory processing may play a role in impaired 
response inhibition.  
Previous genetic investigations on motor control are limited due to small sample sizes 
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(behavioural studies: N=130 to N=405; fMRI studies: N=36 to N=51) and their focus on 
a single motor inhibition task. Most studies selected only one response inhibition task, 
thereby failing to allow the assessment of the specificity of any observed associations 
within the domain of inhibitory function. Moreover, the only response inhibition studies 
combining the two polymorphisms (Congdon et al., 2009; Colzato et al., 2010; Stokes et 
al., 2011; Gurvich and Rossell, 2014; Schneider et al., 2014) did not investigate or report 
statistical interactions of the two polymorphisms with regards to inhibition performance, 
leaving open whether such gene-gene interaction effects may exist.  
Therefore, the first study examines the influence of genetic markers of striatal and 
prefrontal dopamine turnover on a set of inhibitory and cognitive control tasks. In a large 
sample of 515 healthy adults performance measures of a response inhibition battery (see 
Appendix I Methods) was associated with genetic variations of SLC6A3 3'-UTR VNTR 
and COMT rs4680. Additionally, a well powered subsample (N=144) was studied while 
performing the go/no-go, stop-signal and antisaccade tasks in fMRI. Moreover, given the 
conceptual (Congdon, Lesch and Canli, 2008) and empirical (Aichert et al., 2012) link 
between (poor) response inhibition and (high) impulsivity, a psychometric measure of 
impulsivity, the Barratt Impulsiveness Scale was included in the analysis (BIS; Patton, 
Stanford, & Barratt, 1995). Data were examined for main effects of SLC6A3 and COMT 
polymorphism as well as their interactions in order to provide a thorough assessment of 
the role of these dopamine genes in fronto-striatal inhibitory control mechanisms.  
6.1.4 Summary of Key Findings 
There were no significant associations between COMT or SLC6A3 genotype and 
inhibitory performance or impulsivity. These negative findings are in agreement with 
other studies that failed to identify a significant influence of the polymorphisms on 
inhibitory control performance (Krämer et al., 2007; Barnett, Scoriels and Munafò, 2008; 
Congdon et al., 2009; Haraldsson et al., 2009; Stokes et al., 2011; Gurvich and Rossell, 
2014). The three tasks share the recruitment of superior, middle and inferior frontal as 
well as striatal areas (Bari and Robbins, 2013; Criaud and Boulinguez, 2013; Jamadar, 
Fielding and Egan, 2013). Therefore, and given that the primary sites of expression of 
COMT and the SLC6A3 3’-UTR VNTR polymorphism are in the prefrontal cortex and 
striatum, respectively (Ciliax et al., 1999; Matsumoto et al., 2003), both whole-brain 
BOLD analyses and anatomically focussed analyses of superior, inferior and middle 
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frontal gyrus, and caudate and putamen was performed.  
No association of COMT with BOLD was found. However, there were consistent main 
effects of SLC6A3 genotype in all inhibitory contrasts: Homozygosity of the 10R allele 
was associated with greater fronto-striatal BOLD response than genotypes with at least 
one 9R allele (Figure 3). Previous evidence from meta-analyses implies lower striatal 
dopamine transporter expression in 10R homozygotes (Costa et al., 2011; Faraone et al., 
2014). Section 4.2.2 describes a heightened and prolonged extracellular dopamine level 
in animals without or reduced dopamine transporter as well as decreased dopamine 
release. Taken this together, the effects of SLC6A3 on BOLD can be explained by 
heightened and prolonged synaptic dopamine levels in 10/10 carriers, since extracellular 
dopamine level correlates positively with BOLD signal (Knutson and Gibbs, 2007; Schott 
et al., 2008; Fazio et al., 2011; see 7.2).  
 
Figure 3. Key findings Study 1 
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6.1.5 Summary Publication II 
Kasparbauer, A.-M., Rujescu, D., Riedel, M., Pogarell, O., Costa, A., Meindl, T., la 
Fougère, C., Ettinger, U. (2015). Methylphenidate Effects on Brain Activity as a 
Function of SLC6A3 Genotype and Striatal Dopamine Transporter Availability. 
Neuropsychopharmacology, 40(3), 736–745. 
http://doi.org/10.1038/npp.2014.240 (see Appendix B) 
 
A common observation within pharmacological research is the inter-individual difference 
in drug effect and outcome (Shastry, 2006), which also holds for dopaminergic 
compounds like methylphenidate. Therefore, the following publication investigated 
individual differences in response to methylphenidate.  
6.1.6 Methylphenidate and Cognition and Brain Function 
Methylphenidate offers the opportunity to challenge specifically the striatal dopamine 
system due to its binding preferences for dopamine transporter (see 4.2.4). Resting-state 
neuroimaging studies in healthy subjects revealed reduced functional connectivity 
between nucleus accumbens and basal ganglia and medial prefrontal cortex, as well as 
temporal cortex after a single dose of methylphenidate (Ramaekers et al., 2013). Sripada 
and colleagues (2013) found decreased coupling between visual and somatomotor 
networks (Sripada et al., 2013). Additionally, Farr et al. (2014) has described reductions 
in connectivity to the prefrontal cortex and suggest alterations of connectivity caused by 
methylphenidate driving catecholaminergic signalling beyond the normally balanced 
level of functioning and dampening prefrontal activity (Farr, Zhang, et al., 2014). The 
same study has also reported enhanced connectivity to motor cortex and memory circuits. 
Similarly, Mueller and colleagues (2014) have found increased methylphenidate-induced 
connectivity in fronto-parietal networks with sensory-motor and visual cortex, but 
decreased connectivity in cortico-striato-thalamo-cortical structures (Mueller et al., 
2014). Taken together, these findings indicate that the impact of methylphenidate is 
beyond its molecular action site and provides evidence of intrinsic connectivity changes 
to structures important for cognitive functioning.  
One of the earliest studies investigating single dose effects of methylphenidate and 
executive function has found increased attentional recruitment with methylphenidate only 
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under challenging task demands as measured with electroencephalography (Coons et al., 
1981). In another study, using a four-choice reaction time task, single dose of 
methylphenidate increased lateral premotor and medial posterior cortical activation 
measured with fMRI independent of task difficulty (Müller et al., 2005). However 
plasma-concentration was positively correlated with strength of activation in motor and 
premotor cortex, temporoparietal cortex and caudate in the difficult version of the task. 
Similarly, increased recruitment of premotor, cingulate and parietal regions has been 
observed in an object-learning task with increased cognitive load (Bullmore et al., 2003). 
In another learning paradigm methylphenidate reduced hemodynamic response in ventral 
striatum (Dodds et al., 2008). Linssen et al. (2013) has found speeded response times and 
improved delayed memory consolidation, but no impact on neurophysiological markers 
of mental processing (Linssen et al., 2012, 2013). Others showed an enhancement of 
attentional networks during learning and working memory (Anderer et al., 2002; Tomasi 
et al., 2011).  
Marquand and colleagues (2011) have described the effects of methylphenidate during 
working memory as simulating reward during the encoding process (Marquand et al., 
2011). An indication for the selectivity of methylphenidate for task-relevant stimuli. 
During the 2-back (respond to the stimuli that was seen two trials prior) condition of the 
n-back working memory task methylphenidate improved error rate, which was 
accompanied by a reduction in lateral prefrontal activation. In contrast, in boys with 
ADHD methylphenidate upregulated inferior frontal cortex and normalized behavioural 
performance during the 2-back condition (Cubillo et al., 2012). Improved accuracy in a 
conflict-monitoring task was observed by Ivanov and colleagues with methylphenidate 
(2014). Additionally, under the influence of the compound subjects exhibited lower task-
related activity, specifically in reward-related structures irrespective of task difficulty 
(Ivanov et al., 2014). The authors interpreted reduced activation and performance 
improvement in terms of enhanced efficiency of information processing in both reward 
and attentional systems. Similarly, during decision-making methylphenidate dampened 
activation in parietal association cortex and posterior cingulate cortex in comparison to 
placebo. Increased hemodynamic response was observed in bilateral parahippocampal 
and cerebellar activity (Schlösser et al., 2009).  
Several studies investigated methylphenidate-induced changes during inhibitory control 
paradigms. Studies using electroencephalography (EEG) did not find any performance 
effects in a go/no-go paradigm, but an increase of an early event related potential 
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associated with stimuli evaluation during go but not no-go trials (Anderer et al., 2002; 
Hoegl et al., 2011). Hester and colleagues (2012) have found improved capability to 
consciously detect performance errors after methylphenidate administration which was 
linked to reinforced activation difference in dorsal anterior cingulate cortex and inferior 
parietal lobe (Hester et al., 2012). Pauls et al (2012) used a stop-signal paradigm and 
found reduced activation in right inferior frontal gyrus and insula during stop-trials 
(irrespective of motor inhibition) and continuous trials (infrequent go-signals) (Pauls et 
al., 2012). Another study compared methylphenidate-induced changes to brain activity in 
a stop-signal task, but has found only increased putamen activation during failed 
inhibition trials in the go/no-go task (Costa, Riedel, et al., 2013). In contrast, another 
research group revealed increased caudate, motor and inferior parietal cortex activation 
during successful stop trials (Farr, Hu, et al., 2014). Further, Nandam and colleagues 
(Nandam, Hester and Bellgrove, 2014) showed a reduction of caudate activation under 
methylphenidate and increased activation in cingulate cortex. On another cognitive 
control task, the Stroop task, methylphenidate improved error rates and post-error slowing 
and reduced dorsal anterior cingulate activation during errors and increased activation in 
prefrontal cortex (Moeller et al., 2012). A recent meta-analysis confirmed a positive effect 
of methylphenidate on response inhibition and response time variability in young ADHD 
patients (Coghill et al., 2014). 
In sum, administration of methylphenidate demonstrates positive effect on several 
domains of cognition and behavioural control specifically for ADHD patients (Coghill et 
al., 2014). In contrast, in healthy subjects there is mixed evidence in regards to 
methylphenidate-induced enhancement of inhibitory control performance (Turner et al., 
2003; Nandam et al., 2011; Allman et al., 2012; Pauls et al., 2012; Farr, Hu, et al., 2014; 
Manza et al., 2016). A possible predictor for the efficacy of methylphenidate comprises 
dopamine transporter disposition. 
6.1.7 Dopamine Transporter Density  
In addition to genetic predictors, dopamine transporter availability may provide another 
potential baseline predictor of methylphenidate response. Using positron emission 
tomography (PET), Tomasi and colleagues (2009) found a negative correlation between 
striatal dopamine transporter density and deactivation in precuneus and a positive 
correlation with deactivation in the ventral anterior cingulate (BA 24/32) during visual 
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attention paradigm (Tomasi et al., 2009). Additionally, SPECT-quantified striatal 
dopamine transporter availability has previously been associated with treatment outcome 
in ADHD (la Fougère et al., 2006). In healthy, increased striatal binding of a dopamine 
transporter radiotracer was associated with decreased BOLD activation in the 
supplementary motor area during performance of a motor task (Fazio et al., 2011). 
However, no studies investigated dopamine transporter availability as predictor of 
methylphenidate effects on neural or cognitive measures. Recent meta-analyses attribute 
higher striatal dopamine transporter availability to SLC6A3 3’-UTR VNTR 9R carriers 
(Costa et al., 2011; Faraone et al., 2014), calling for a combination of these two potential 
predictors. 
6.1.8 Rational of the Study 
Summing up, the effects of methylphenidate on cognition are mixed and even within the 
same cognitive domain inconsistent. The second publication, examines potential 
molecular and genetic predictors of the dopamine transporter that could explain inter-
individual variability of methylphenidate-induced changes. Thus, SLC6A3 3’-UTR 
VNTR (see 4.2.3) and dopamine transporter density in striatal structures serve as potential 
predictors of hemodynamic response and performance in an inhibitory control task. Only 
few pharmacogenetic studies are available on the SLC6A3 genotype-dependent cognitive 
or neural response to methylphenidate. Loo and colleagues (Loo et al, 2003) found the 
VNTR to predict methylphenidate effects on behavioural performance and the 
electroencephalographic response in children with ADHD. Further evidence of the 
influence of the VNTR on methylphenidate effects comes from a transcranial magnetic 
stimulation study of cortical inhibitory activity in ADHD (Gilbert et al, 2006). However, 
so far there are no investigations of SLC6A3 and methylphenidate-induced changes in 
BOLD in healthy subjects. 
To identify genetic and molecular predictors of methylphenidate-induced changes in 
brain activity during response inhibition and pharmacologically, healthy male participants 
were challenged with a single dose methylphenidate during a response inhibition task. 
Briefly, BOLD response of fifty healthy males during a go/no-go task under the influence 
of 40mg methylphenidate and placebo was reassessed with genotype group as between 
subject factor. Additionally in a subset of thirty-five participants, baseline striatal 
dopamine transporter availability was ascertained with 123I-FP-CIT SPECT and 
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correlated with amount of methylphenidate-induced change in hemodynamic response 
and behaviour. 
6.1.9 Summary of Key Findings 
No associations in behavioural task performance between genotype groups or striatal 
binding was detected. However, an interaction between the genetic variants of the 
SLC6A3 3’-UTR VNTR polymorphism and drug condition was found. During successful 
inhibition of a motor response, methylphenidate induced an increase of BOLD signal for 
carriers of 9R-allele and a decrease in 10/10 homozygotes in brain areas associated with 
motor inhibition (Figure 4). Interaction clusters fall within the typical task network 
(Criaud and Boulinguez, 2013) and areas modulated by methylphenidate during 
inhibition (Pauls et al., 2012; Nandam, Hester and Bellgrove, 2014), including anterior 
cingulate and right lateralized prefronto-parieto-temporal structures.  
Furthermore, striatal dopamine transporter availability was nominally greater in 9R 
carriers compared to 10/10 homozygotes (d=.40), in line with meta-analyses (Costa et al., 
2011; Faraone et al., 2014), but did not predict BOLD or behavioural changes following 
Figure 4. Key findings Study 2 
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methylphenidate administration.  
These results show the effect of acute methylphenidate administration on brain activation 
is dependent on dopamine transporter genotype. During successful inhibition 9R carriers 
responded with an increase of brain activation whereas a reduction was observed in 10/10 
carriers. The pattern in the placebo condition is qualitative similar to the previous study 
in which 10/10 carriers exert higher BOLD during inhibitory processes (see 7.2). SPECT 
data qualitatively confirms increased dopamine transporter density in 9R carriers, 
therefore an explanation for increased BOLD activity after the administration of a 
dopaminergic agonist might be increased dopamine release in this genotype group similar 
to a rewarding stimulation (Dreher et al., 2009). 
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6.2 Summary Publication III 
Kasparbauer, A.-M., Meyhöfer, I., Steffens, M., Weber, B., Aydin, M., Kumari, V., 
Hurlemann, R., Ettinger, U. (2016). Neural effects of methylphenidate and 
nicotine during smooth pursuit eye movements. NeuroImage, 141, 52–59. 
http://doi.org/10.1016/j.neuroimage.2016.07.012 (see Appendix C) 
6.2.1 Effects of Methylphenidate and Nicotine on Cognition 
Although, there was no pro-cognitive effect of methylphenidate in study 2, there are 
several reports of improved cognitive performance during spatial working memory, 
sustained attention and in more complex tasks including planning and attentional-set 
shifting (Mehta and Riedel, 2006; Linssen et al., 2014). Reports on methylphenidate-
induced pro-cognitive effects on attention-based tasks (Bagot and Kaminer, 2014) has led 
to its popularity among students as cognitive enhancer (Outram, 2010). Although there 
may be ethical concerns surrounding the issue of cognitive enhancement (Hyman, 2011), 
it is of considerable scientific interest to further investigate the potential of 
biotechnological interventions to enhance human cognition. One of the aims of such 
investigations is to increase knowledge on the specific and shared neuronal underpinnings 
of enhancing compounds. 
Similar to methylphenidate, nicotine is also known to have beneficial effects on attention 
and memory (Warburton, 1992). Previous literature confirms overlapping effects of these 
compounds on different attentional tasks in humans (Koelega, 1993), but also differential 
effects on attention measures in rodents (Bizarro et al., 2004). So far, there has been no 
direct comparison of these two stimulating agents in healthy humans. Recent ethical 
debates on pharmaceutical cognitive enhancement in healthy (Fond et al., 2015; Maier et 
al., 2015; Whetstine, 2015; Marraccini et al., 2016) and the high variability in treatment 
effectiveness of dopamine targeting compounds in patients (Kelton et al., 2000; Cools, 
2006; Kieling et al., 2010; Martinez et al., 2011; Jasinska et al., 2014) demand a clearer 
picture of the stimulating effects of these two compounds on cognition and brain function. 
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6.2.2  Nicotine and Cognition and Brain Function 
Nicotine is the pharmacological component to addictive tobacco smoking behaviour 
(Stolerman, Mirza and Shoaib, 1995; Di Chiara, 2000; Balfour, 2002a, 2002b; Mathieu-
Kia et al., 2002) and its psychopharmacological effects are diverse in healthy and patient 
population (Kelton et al., 2000; De Biasi and Dani, 2011; Hahn, 2015). Nicotine binds to 
nicotinic acetylcholine receptors (nAChR) across the cortex and potentiates the cortical 
and subcortical release of acetylcholine, dopamine, noradrenaline and other transmitter 
types (Role and Berg, 1996; MacDermott, Role and Siegelbaum, 1999; López et al., 2001; 
Wonnacott et al., 2006; Wallace and Porter, 2011). Nicotine modulates dopaminergic 
neurotransmission by enhancing dopamine release in the mesocorticolimbic and 
nigrostriatal systems (Clarke and Pert, 1985; Changeux et al., 1998; Laviolette and van 
der Kooy, 2004). The compound is subject to intensive research not only due to its 
addictive potential, but also because of its pro-cognitive effects. A plethora of studies 
exists, which investigate enhancement effects of nicotine on motor control, sensory 
processing, alertness, attention and memory (Heishma, Taylor and Henningfield, 1994; 
Heishman, Kleykamp and Singleton, 2010).  
There is consistent evidence of nicotinic enhancement of attention in human literature 
(Stolerman, Mirza and Shoaib, 1995; Newhouse, Potter and Singh, 2004; Heishman, 
Kleykamp and Singleton, 2010), which is thought to enable performance improvement in 
higher cognitive operations. Attentional enhancement of nicotine is mediated by two 
mechanisms: the stimulation of α4β2* nicotinic acetylcholine receptors on glutamatergic 
neurons and the increase in tonic levels of acetylcholine (Demeter and Sarter, 2013). This 
linkage is strongly supported by the observed attentional impairments in clinical 
population with nAChR hypofunction (Nordberg et al., 1995; Stolerman, Mirza and 
Shoaib, 1995; Perry et al., 2000; Singh, Potter and Newhouse, 2004; Adams and Stevens, 
2007; Petrovsky et al., 2010; Kendziorra et al., 2011).  
Moreover, via nAChR subtypes (Wonnacott et al., 2006), nicotine induces dopamine 
release in the nucleus accumbens (Pontieri et al., 1996; Di Chiara et al., 2004), a structure 
enriched with dopamine transporter (Ciliax et al., 1999). At neurophysiological level, 
acute nicotine demonstrates higher potency for mesolimbic dopamine neurons and effects 
are more observable in dopamine neurons in the ventral tegmental area rather than 
substantia nigra (Kalivas, 1993).  
Nonetheless, nicotinic receptors are also located on nigrostriatal pathway (Clarke and 
Pert, 1985) and an increase in ventral striatal dopamine level after acute administration 
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was found with PET (Brody et al., 2004); others have found no association of nicotine 
with overall striatal dopamine availability (Montgomery et al., 2007). Few studies 
propose that nicotine induces increased dopamine transporter function (Hart and Ksir, 
1996).  
At cognitive level, acutely administered nicotine reduces attentional dysfunction in 
patients with neurodegenerative diseases (Levin and Rezvani, 2002; Singh, Potter and 
Newhouse, 2004), schizophrenia (Petrovsky et al., 2010) and ADHD (Levin et al., 1996); 
in healthy individuals the enhancing effects on cognitive performance are less 
pronounced, but confirm positive effects on alertness, attention motor control and 
memory observed (Sacco, Bannon and George, 2004; Heishman, Kleykamp and 
Singleton, 2010). 
Effects of nicotine on BOLD response are heterogeneous. Whilst some studies report 
increased activation in task-relevant networks along with attentional enhancement 
(Lawrence, Ross and Stein, 2002), others find decreased activation and performance 
improvement (Thiel, Zilles and Fink, 2005; Giessing et al., 2006; Hahn et al., 2007; 
Warbrick et al., 2011). Nicotine-induced reduction of task relevant activation has been 
associated with early attentional functions independent of task conditions (Hahn et al., 
2009).  
Routes of administration include subcutaneous injection (Ettinger et al., 2009), nasal 
spray (Warbrick et al., 2011), oral gums (Giessing et al., 2006) and transdermal patches 
(Petrovsky et al., 2013). 
6.2.3 Smooth Pursuit Eye Movements 
For the investigation of performance-enhancing effects, it may be advantageous to use 
simple tasks of sensory or motor functions. It can be difficult to separate stimulant-
induced enhancement of sensory or motor functions in attention, learning and memory. 
Oculomotor tasks offer the opportunity to measure pharmacological effects on cognitive 
and motor functions (Reilly et al., 2008). The kinematics and dynamics of the eyeball are 
straightforward (Robinson, 1964, 1965) and different movement types are generated by 
separate neural systems (Berman et al., 1999). 
For example, the smooth pursuit eye movement (SPEM) task requires a mechanism to 
track a moving object in extra-personal space without head movement and draws upon 
attention, motion processing and temporo-spatial prediction (Barnes, 2008). The neural 
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correlates of the required sensorimotor feedback system are well established and include 
motion processing regions, such as area V5, and attention and prediction-related regions 
in frontal and parietal cortices, namely frontal, parietal and supplementary eye fields and 
subcortical structures such as thalamus and putamen (Thier and Ilg, 2005; Lencer and 
Trillenberg, 2008; Meyhöfer et al., 2015). 
The pursuit system is a negative feedback control system, where the afferent pathways 
detect stimuli motion and the efferent pathways stimulate the eyeball in an effort to match 
eye and target motion (Lisberger, Morris and Tychsen, 1987). Performance can be 
measured globally as deviation between target and eye position by calculating the root 
mean square error (RMSE) of eye position. However, specific measures such as steady 
state velocity gain, eye velocity and saccadic frequency are also used to assess pursuit 
performance (Nagel et al., 2006; O’Driscoll and Callahan, 2008; Levy et al., 2010; 
Meyhöfer et al., 2015; Steffens et al., 2016). 
Several studies have found beneficial effects of nicotine on smooth pursuit performance 
in smokers (Klein and Andresen, 1991; Domino, Ni and Zhang, 1997; Olincy et al., 1998; 
Dépatie et al., 2002), but not in non-smokers (Avila et al., 2003; Schmechtig et al., 2013). 
This suggests that previous findings of nicotinic enhancement may have been confounded 
by the operation of withdrawal effects. It should also be noted that some studies found 
adverse effects of nicotine on smooth pursuit performance (Sibony, Evinger and 
Manning, 1988; Thaker et al., 1991). 
6.2.4 Rational of the Study 
Both nicotine and methylphenidate have been shown to enhance overlapping measures of 
attentional performance (Levin et al., 2001; Bizarro et al., 2004) and smooth pursuit 
(Sherr et al., 2002; Allman et al., 2012). For better understanding of the common and 
distinct mechanisms of action, the third study assessed the effects of single doses of 
nicotine and methylphenidate on smooth pursuit eye movements.  
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Eighty-two healthy male non-smokers performed a smooth pursuit eye movement task 
while recording eye movement and hemodynamic response via 3T scanner. A between-
subjects, double-blind design was applied. Each subjects was randomly assigned to one 
of three groups: placebo (placebo patch and capsule), nicotine (7mg nicotine patch and 
placebo capsule), or methylphenidate (placebo patch and 40mg methylphenidate 
capsule). The task comprised of blocks of sinusoidal target movement with either high 
(0.4 Hz) or low (0.2 Hz) frequency and blocks of no target movement (fixation). 
6.2.5 Summary of Key Findings 
On the behavioural level, no significant group difference was observed on any key 
behavioural measure of smooth pursuit, namely maintenance gain, saccadic frequency or 
mean RMSE. On the neural level, there was a main effect of drug group in the left frontal 
eye field (FEF). Increased activation was observed in the methylphenidate group 
compared to nicotine, with an intermediate response in the placebo group (Figure 5). The 
FEFs are a key region in the control of eye movements. During pursuit the FEFs are 
thought to regulate pursuit maintenances and also initiation and prediction of target 
movement (Lencer and Trillenberg, 2008). The FEFs receive subcortical input from 
superior colliculus and substantia nigra (Lynch, Hoover and Strick, 1994). Cholinergic 
stimulation of superior colliculus leads to improved initiation of eye movements (Aizawa 
et al., 1999), whereas electrical stimulation of substantia nigra operates bidirectionally 
and either suppresses or enhances pursuit movement (Basso, Pokorny and Liu, 2005). 
Presumably methylphenidate exerts its effects via the nigrostriatal system originating 
Figure 5. Key findings Study 3 
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from the substantia nigra (John and Jones, 2007). The importance of an intact nigrostriatal 
system during pursuit performance has been demonstrated in Parkinson patients (White 
et al., 1983). Thus, increased activity in the methylphenidate group reflects the 
enhancement of task relevant networks and confirms its role in the selection of salient 
stimuli (Benoit-Marand, Jaber and Gonon, 2000; Volkow et al., 2004, 2005) as opposed 
to a compound with similar prodopaminergic effects independent of dopamine transporter 
blockage (see 7.3).  
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7. General Discussion 
The dopamine transporter contributes crucially to dopaminergic transmission by affecting 
basal dopamine levels, postsynaptic receptor density and dopamine synthesis (4.2.2). The 
current work provides a linkage between genetic predisposition of the human dopamine 
transporter with neural correlates of inhibitory control and with response to 
pharmaceutical blockage of the dopamine transporter. The third study revealed dissimilar 
effects on task network between dopamine transporter blockage and nicotinic stimulation 
during a oculomotor task.  
7.1 Cognition and Behaviour 
The assessed dopamine transporter genotype (SLC6A3 3’-UTR) modulates activity in 
frontal and subcortical structures during inhibition of motor responses, which was seen 
by a consistent effect on hemodynamic response of the polymorphism on tasks of motor 
and oculomotor inhibition (Figure 3). Subjects homozygous for the 10 allele had 
significantly higher BOLD activity in comparison to 9R heterozygotes. These findings 
are consistent with previous evidence (Braet et al., 2011). For example, a qualitatively 
similar pattern was found during reward anticipation and memory in the striatum and 
hippocampus, respectively (Wittmann et al., 2013). Considering previous studies 
reporting worse response inhibition (Braet et al., 2011; Cornish et al., 2011) and increased 
impulsive behaviour (Gizer and Waldman, 2012; Mata et al., 2012), the present findings 
are indicative of less efficient cognitive control mechanisms in 10R homozygotes. 
Furthermore, the second study qualitatively replicates the genotype difference in 
activation and reveals variability of BOLD response to a dopaminergic agonist as function 
of the dopamine transporter genotype. Genotype modulated task relevant brain activation 
in response to a dopamine reuptake inhibitor (Figure 4). For a subsample, dopamine 
transporter density was also available, however no influence of striatal dopamine 
transporter density on BOLD signal was found.  
While the 10/10 carriers showed a reduction in BOLD signal, the 9R carriers who are 
thought to have higher dopamine transporter density (Costa et al., 2011; Faraone et al., 
2014), demonstrated an increase of activation after pharmacological challenge. The 
observation of increased drug sensitivity in 9R carriers is in in line with rodent studies 
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demonstrating increased sensitivity to drug-induced effects for animals with an 
overexpression of dopamine transporters and with studies on reward-sensitivity 
(Salahpour et al., 2008; Dreher et al., 2009; Forbes et al., 2009; Franklin et al., 2009). 
Inhibitory motor control networks are an integrative part of cognitive control function 
(Aron, 2007). The unquestionable role of dopamine in motivation in addition to the 
present influence on cognitive control mechanisms underlines the regulatory role of the 
dopamine transporter in goal-directed behaviour. This is further supported by findings 
that indicate dopamine transporter genotype effects on social behaviour (Enter, Colzato 
and Roelofs, 2012). In sum, despite the negative findings of an association of the 
polymorphism and performance in various cognitive domains (Ettinger, Merten and 
Kambeitz, 2016), the present results indicate an essential role of the transporter in the 
adaptive regulation of cognition and behaviour.  
7.2 Modulation of BOLD by SLC6A3 3’-UTR VNTR 
An important question is how the dopamine transporter genotype influences neural 
activity measured with BOLD. Multi-modal neuroimaging research has shown positive 
associations between BOLD signal and dopamine release as well as extracellular 
dopamine (Chen et al., 1997; Knutson and Gibbs, 2007; Schott et al., 2008) and 
established a link between phasic firing of dopaminergic neurons with increased BOLD 
signal (Lohani et al., 2016). Furthermore, increased BOLD activation in the absence of 
performance differences can be indicative of less efficient processing, i.e. for example 
more effort which requires the recruitment of extra neural resources (Ritsner, 2009; 
Poldrack, 2015). 
Rodent studies with DAT KO or deficient mice suggest increased extracellular dopamine 
levels (hyperdopaminergic) with lower dopamine transporter availability and in DAT-tg 
mice reduced extracellular dopamine levels (hypodopaminergic) with higher dopamine 
transporter density along with higher dopamine release (see 4.2.2). If this concept is 
applied to the genotype groups, increased BOLD in the 10/10 carriers who are thought to 
have higher dopamine transporter availability (Costa et al., 2011; Faraone et al., 2014) 
could reflect higher potency of phasic transmission along with increased extracellular 
dopamine levels. The enhancement of extracellular dopamine level via blockage of 
dopamine transporter with methylphenidate and the consequential reduction of BOLD is 
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possibly caused by autoreceptor regulation (Lacey, Mercuri and North, 1987), or the 
transition from phasic to tonic firing as suggested by the model of Dreher and Hounsgaard 
(2012). Increased dopamine levels in the striatum in DAT-knockout mice has been 
associated with hyperactivity symptoms (4.2.2), in this context the heightened activation 
of 10/10 carriers could be interpreted as heightened effort to suppress an unwanted 
response and the generally enhanced dopamine level might be indicative of an increased 
potency to act on impulse. For example, decreased striatal dopamine transporter density 
and increased dopamine has been demonstrated in patients with restless legs syndrome 
(Earley et al., 2011, 2013). However, this simplifies the processes of goal-directed action 
and a thorough explanation requires the dissection of inhibition and motor action 
networks. Nonetheless, the findings are in line with the genotype group’s association of 
impaired response inhibition in ADHD (Cornish et al., 2005), as well as impulsive 
behaviour in healthy (Mata et al., 2012).  
7.3 Methylphenidate and Nicotine 
During an oculomotor task, the blockage of dopamine transporter with the compound 
methylphenidate resulted in an increase of frontal eye field activity in contrast to nicotine. 
The frontal eye fields are associated with spatial attention (Corbetta et al., 1998) and 
voluntary eye movement control (Pierrot-Deseilligny, Milea and Müri, 2004). 
Methylphenidate-induced increase in dopamine is more effective when given 
concomitantly with a salient stimuli (Volkow et al., 2005). Thus, the methylphenidate-
induced enhancement of task-relevant areas goes in line with the compounds effects on 
stimuli saliency (Volkow et al., 2005; Linssen et al., 2012; Farr, Hu, et al., 2014). A 
moving stimulus is by itself a very salient visual input, when contrasted to a stationary 
target, as was done in study 3. Therefore, the observed differences in drug effects on 
frontal eye field may derive from dissimilar effects on baseline condition. If nicotine 
generally enhances neural processing regardless of stimuli saliency, one would expect 
smaller signal change compared to placebo. This is supported by the observation that 
nicotine enhances extra-striate cortex a region that closely interacts with frontal eye fields 
(Silvanto, Lavie and Walsh, 2006) in the absence of visual stimulation (Tanabe et al., 
2011). Consequently, nicotine reduction of BOLD could reflect lower signal-to-noise 
ratio for task relevant activation. In contrast, methylphenidate-induced increase of BOLD 
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during task and lower impact on baseline condition implies increased signal-to-noise-
ratio. While such argumentation needs further proof, including assessment of baseline 
effects in a within subjects design, it agrees with the observed intermediate BOLD 
response to placebo.  
Another possible explanation includes efficiency effects of nicotine and are described in 
more detail in 11.3 Appendix C (Publication III)(0).  
The effects in studies with methylphenidate are very heterogeneous as well as effects of 
nicotine on dopaminergic function. An emerging pattern caused by variations in 
dopamine release is an inverted-u shaped dose-response profile of post-synaptic 
dopamine effects (Seaman, Yang, 2004). It appears that the dopamine systems are “tuned” 
so that low or high levels of dopamine activity impair performance in motor, behavioural 
or cognitive domains, which would be in line with switching from phasic to tonic activity 
as discussed in 4.2.2 (Robbins and Arnsten, 2009).  
Additionally, inter-individual difference in response to nicotine and methylphenidate 
might mask other effects. Future studies on prodopaminergic enhancement of cognition 
would benefit from the inclusion of genetic and molecular markers as well as dose 
variation.  
7.4 Methodological Considerations 
Several limitations to the current studies have to be addressed. Pharmacological studies 
were only conducted on male subjects to reduce influence of hormonal fluctuations. This 
selection strategy maximizes sample homogeneity in terms of genetics and avoids 
influences of hormonal fluctuations in females but comes at the cost of reduced 
generalizability. The generalizability of the findings is limited to healthy, Caucasian 
males. Inclusion of female subjects would give a more realistic picture of 
psychopharmacological effects on dopaminergic transmission in normal healthy 
population. Additionally, an increase of sample size, specifically for each individual 
sample size of genotype groups would allow furthering dissecting the mechanisms 
leading to a different BOLD signal in the current studies and allow for greater sensitivity 
for small magnitude effects.  
Only most frequent allelic variants were investigated, yet thorough investigation with 
candidate gene approach would benefit from inclusion of other variants and evenly 
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distributed heterozygotic 9R groups. A further limitation is the focus on a single 3’-UTR 
VNTR, which is only one of several polymorphisms thought to regulate striatal dopamine. 
Cummins and colleagues (Cummins et al., 2012) completed the largest study yet to test 
linkage of catecholamine gene and response inhibition phenotype. Robust associations 
were found in the SLC6A3 gene, the markers included the rs46000 and the rs37020 
variants. Further, neuroimaging revealed an additive association between variants in the 
rs37020 allelic variants and task-related brain activation during stop-signal performance 
in prefrontal and striatal areas.  
Further considerations include the affinity of methylphenidate to noradrenergic 
transporter (Hannestad et al., 2010; Dela Peña, Gevorkiana and Shi, 2015) and the 
compounds potency to enhance dopamine transport into membrane-associated vesicles 
(Volz et al., 2007). Further studies, are needed to clarify impact of noradrenergic 
transporter blockage.  
Further issues arise from limitations in imaging techniques. SPECT method is limited by 
the semi-quantitative assessment of dopamine transporter, which however is inherent to 
most receptor and transporter SPECT and PET studies.  
Future combined PET-fMRI investigations with dopamine transporter displacement 
measured after drug administration or with dopamine imaging as marker of dopamine 
release might elucidate further dependencies between molecular and genetic factors 
influencing the dopamine system during cognitive performance.  
7.5 Concluding remarks 
The current thesis links genetic and molecular characteristics of the dopamine transporter 
to neural activity and confirms functionality of the transporter as well as its potential use 
as non-invasive measure of dopaminergic activity in healthy subjects. Albeit a limitation, 
the homogeneous sample group of healthy male non-smokers and the well-powered 
samples in each study are also strength of the current work and an opportunity to gain 
knowledge on pharmaceutical and genetic effects in the absence of confounding factors, 
e.g. pathology, pharmacological treatment. The results highlight the power of candidate 
gene approach and allow assumptions on dopamine transporter effects on dopamine flux 
and the associated cognitive processes. Findings complement the understanding of 
regulatory impact on cognition and goal-directed behaviour as function of dopamine 
General Discussion: Concluding remarks 
54 
transporter and present genetic markers as predictor of treatment response variability.  
In sum, the quality of the current neuroscientific work lies in the combination of 
knowledge from animal research and the application of multimodal imaging, including 
genetic and pharmacological fMRI and its findings help to shape a more precise 
functional role of the dopamine transporter in cognition. 
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